Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBITDA (2018 - 2025)

Historic EBITDA for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to -$23.8 million.

  • Neurogene's EBITDA fell 729.49% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 2833.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 4861.56% down from last year.
  • As of Q3 2025, Neurogene's EBITDA stood at -$23.8 million, which was down 729.49% from -$26.1 million recorded in Q2 2025.
  • Neurogene's 5-year EBITDA high stood at -$12.6 million for Q2 2023, and its period low was -$26.1 million during Q2 2025.
  • For the 3-year period, Neurogene's EBITDA averaged around -$19.5 million, with its median value being -$20.1 million (2024).
  • In the last 5 years, Neurogene's EBITDA crashed by 5984.44% in 2024 and then tumbled by 729.49% in 2025.
  • Quarter analysis of 3 years shows Neurogene's EBITDA stood at -$14.7 million in 2023, then plummeted by 46.01% to -$21.5 million in 2024, then fell by 10.63% to -$23.8 million in 2025.
  • Its EBITDA was -$23.8 million in Q3 2025, compared to -$26.1 million in Q2 2025 and -$25.9 million in Q1 2025.